NCT04518345View on ClinicalTrials.gov

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

October 13, 2021

Study Completion Date

December 22, 2021

Conditions
Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given IV

DRUG

Dubermatinib

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

Uma Borate

OTHER

NCT04518345 - TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter